Communiqués Waverley Pharma Inc.

Actions

WAVE

CA94357L1058

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. 16:31:13 31/08/2026			Varia. 5j.	Varia. 1 janv.
0,0200 ^CAD	+33,33 %		+33,33 %	-

28/08	Waverley Pharma Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
22/05	Waverley Pharma Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

17/07	Waverley Pharma Announces Chief Financial Officer Change	AQ
24/09/24	Waverley Pharma Acquires US based Pharmacy	AQ
20/06/24	Waverley Pharma Announces Annual and Special Meeting Election Results	AQ
23/05/24	Waverley Pharma : Notice of meeting	PU
23/05/24	Waverley Pharma : Information circular	PU
01/05/24	Waverley Pharma Business Update	AQ
22/11/23	Waverley Pharma Announces Changes to Board of Directors	AQ
02/08/23	Waverley Pharma Business Update	AQ
20/03/23	Waverley Pharma Provides Business Update	AQ
11/01/23	Waverley Pharma Provides Update on its PARP-1 Inhibitor Program	AQ
05/08/21	Waverley Pharma : Announces $3,000,000 Credit Facility	AQ
27/05/21	Waverley Pharma : Announces Successful Tender Award for Pemetrexed with NHS England	AQ
18/01/21	Waverley Pharma : Announces Successful Tender Award for Capecitabine with NHS Scotland	AQ
12/11/20	Waverley Pharma : Announces Tentative ANDA Approval for Pemetrexed in the United States	AQ
23/09/20	Waverley Pharma Announces Listing on the Frankfurt Stock Exchange (FSE: 5GZ)	AQ
08/09/20	Waverley Pharma : Announces Signing of Term Sheet to Acquire Exclusive Rights to Market Six Generic Oncology Products in the United States	AQ
25/08/20	Waverley Pharma : Announces Grant of Market Authorization for Pemetrexed in Spain and Bortezomib in Italy	AQ
30/07/20	Waverley Pharma : Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries	AQ
25/06/20	Waverley Pharma : Announces Collaboration with Dr. David E. Herbert and the University of Manitoba for the Development of a Synthetic Library of Chloroquine Analogs to Treat COVID-19	AQ
28/04/20	Waverley Pharma : Announces Reliance on Relief from Filing Requirements for Annual Financial Statements	AQ
03/02/20	Waverley Pharma : Announces Appointment of New President and CEO	AQ
08/01/20	Waverley Pharma : Announces Executive Leadership Changes	AQ
17/12/19	Waverley Pharma : Announces Grant of Marketing Authorization in the United Kingdom for Erlotinib	AQ